Yengi Lilian G, Leung Louis, Kao John
Drug Metabolism Division, Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA.
Pharm Res. 2007 May;24(5):842-58. doi: 10.1007/s11095-006-9217-9. Epub 2007 Mar 1.
Drug metabolism in pharmaceutical research has traditionally focused on the well-defined aspects of absorption, distribution, metabolism and excretion, commonly-referred to ADME properties of a compound, particularly in the areas of metabolite identification, identification of drug metabolizing enzymes (DMEs) and associated metabolic pathways, and reaction mechanisms. This traditional emphasis was in part due to the limited scope of understanding and the unavailability of in vitro and in vivo tools with which to evaluate more complex properties and processes. However, advances over the past decade in separate but related fields such as pharmacogenetics, pharmacogenomics and drug transporters, have dramatically shifted the drug metabolism paradigm. For example, knowledge of the genetics and genomics of DMEs allows us to better understand and predict enzyme regulation and its effects on exogenous (pharmacokinetics) and endogenous pathways as well as biochemical processes (pharmacology). Advances in the transporter area have provided unprecedented insights into the role of transporter proteins in absorption, distribution, metabolism and excretion of drugs and their consequences with respect to clinical drug-drug and drug-endogenous substance interactions, toxicity and interindividual variability in pharmacokinetics. It is therefore essential that individuals involved in modern pharmaceutical research embrace a fully integrated approach and understanding of drug metabolism as is currently practiced. The intent of this review is to reexamine drug metabolism with respect to the traditional as well as current practices, with particular emphasis on the critical aspects of integrating chemistry and biology in the interpretation and application of metabolism data in pharmaceutical research.
在药物研发中,药物代谢传统上主要关注吸收、分布、代谢和排泄这些明确的方面,通常称为化合物的ADME性质,特别是在代谢物鉴定、药物代谢酶(DMEs)及相关代谢途径的鉴定以及反应机制等领域。这种传统的重点部分归因于理解范围有限以及缺乏用于评估更复杂性质和过程的体外和体内工具。然而,在过去十年中,药物遗传学、药物基因组学和药物转运体等独立但相关领域取得的进展极大地改变了药物代谢模式。例如,对DMEs遗传学和基因组学的了解使我们能够更好地理解和预测酶调节及其对外源(药代动力学)和内源途径以及生化过程(药理学)的影响。转运体领域的进展为转运体蛋白在药物吸收、分布、代谢和排泄中的作用以及它们在临床药物 - 药物和药物 - 内源性物质相互作用、毒性和药代动力学个体间变异性方面的后果提供了前所未有的见解。因此,参与现代药物研发的人员必须采用目前实践中完全整合的方法并理解药物代谢。本综述的目的是重新审视药物代谢方面的传统及当前实践,特别强调在药物研发中代谢数据的解释和应用中整合化学和生物学的关键方面。